New biotech venture fund capitalized at $300 million

Pivotal bioVenture Partners2Pivotal bioVenture Partners closed its first fund last week, securing $300 million to invest in biotech start-ups. Click here to learn more about the new fund.

Tom Ballard

By Tom Ballard, Chief Alliance Officer,
Pershing Yoakley & Associates. P.C.

eNews & Updates

Sign up to receive posts via email.

Connect With Us

Upcoming Events

Links to Partners